PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 19154443-11 2009 The PDE4 inhibitor diminished bleomycin-induced transcripts for tumour necrosis factor (TNFalpha), transforming growth factor (TGFbeta), connective tissue growth factor, alphaI(I)collagen, endothelin-1 and the mucin, Muc5ac, in lung, and reduced bronchoalveolar lavage fluid levels of TNFalpha, interleukin-13, TGFbeta, Muc5ac, lipid hydroperoxides and inflammatory cell counts. Bleomycin 30-39 tumor necrosis factor Rattus norvegicus 88-96 20510675-5 2010 AS605240 also inhibited augmented expression of TNF-alpha and IL-1beta induced by bleomycin instillation. Bleomycin 82-91 tumor necrosis factor Rattus norvegicus 48-57 19154443-11 2009 The PDE4 inhibitor diminished bleomycin-induced transcripts for tumour necrosis factor (TNFalpha), transforming growth factor (TGFbeta), connective tissue growth factor, alphaI(I)collagen, endothelin-1 and the mucin, Muc5ac, in lung, and reduced bronchoalveolar lavage fluid levels of TNFalpha, interleukin-13, TGFbeta, Muc5ac, lipid hydroperoxides and inflammatory cell counts. Bleomycin 30-39 tumor necrosis factor Rattus norvegicus 285-293 15713430-8 2005 Bleomycin-induced pulmonary injury and lung fibrosis was indicated by increased lung hydroxyproline content, and elevated nitric oxide synthase, myeoloperoxidase, platelet activating factor, and tumor necrosis factor-alpha in lung tissues. Bleomycin 0-9 tumor necrosis factor Rattus norvegicus 145-222 18462759-9 2008 Immunohistochemical studies revealed that DAS reduced the bleomycin-induced activation of inducible nitric oxide synthase (iNOS) and nuclear factor kappa-B (NF-kappaB) and decreased the augmented levels of the early inflammatory cytokines, tumour necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta), in the lung tissues. Bleomycin 58-67 tumor necrosis factor Rattus norvegicus 270-279 16879498-9 2006 5 Circulating plasma levels of TNF-alpha/IL-1beta were augmented in bleomycin-exposed rats compared with controls. Bleomycin 68-77 tumor necrosis factor Rattus norvegicus 31-40 15713430-11 2005 Co-administration of bleomycin and mesna reduced bleomycin-induced weight loss and attenuated lung injury as evaluated by the significant reduction in hydroxyproline content, nitric oxide synthase activity, and concentrations of myeoloperoxidase, platelet activating factor, and tumor necrosis factor-alpha in lung tissues. Bleomycin 21-30 tumor necrosis factor Rattus norvegicus 229-306 15713430-11 2005 Co-administration of bleomycin and mesna reduced bleomycin-induced weight loss and attenuated lung injury as evaluated by the significant reduction in hydroxyproline content, nitric oxide synthase activity, and concentrations of myeoloperoxidase, platelet activating factor, and tumor necrosis factor-alpha in lung tissues. Bleomycin 49-58 tumor necrosis factor Rattus norvegicus 229-306 15371238-1 2004 Tumor necrosis factor-alpha (TNF-a) is produced by alveolar macrophages (AM) in response to bleomycin (BLM) exposure. Bleomycin 92-101 tumor necrosis factor Rattus norvegicus 0-27 15371238-1 2004 Tumor necrosis factor-alpha (TNF-a) is produced by alveolar macrophages (AM) in response to bleomycin (BLM) exposure. Bleomycin 92-101 tumor necrosis factor Rattus norvegicus 29-34 9221384-11 1997 Tumor necrosis factor alpha (TNF-alpha) has been shown to be a key cytokine in bleomycin-induced fibrosing alveolitis as well as in IPF; it also exerts catabolizing effects. Bleomycin 79-88 tumor necrosis factor Rattus norvegicus 0-27 10991907-7 2000 Furthermore, curcumin remarkably suppressed the BLM-induced alveolar macrophage production of TNF-alpha, superoxide and nitric oxide. Bleomycin 48-51 tumor necrosis factor Rattus norvegicus 94-103 11480082-6 1998 RESULT: The levels of TNF-alpha mRNA in lungs of bleomycin groups on days 3,7 were significantly higher than those of control group (t = 10.33 and 12.54 respectively; P < 0.01). Bleomycin 49-58 tumor necrosis factor Rattus norvegicus 22-31 11480082-10 1998 The increased expression of TNF-alpha gene may play an important role in the early events of bleomycin-induced pulmonary fibrosis. Bleomycin 93-102 tumor necrosis factor Rattus norvegicus 28-37 9390197-3 1997 On the other hand, low-dose bleomycin restored the macrophage cytotoxic activities, NO production, IFN gamma mRNA expression and TNF alpha production in the KDH-8-bearing rats. Bleomycin 28-37 tumor necrosis factor Rattus norvegicus 129-138 9441129-10 1997 In conclusion, EM can ameliorate bleomycin-induced pulmonary fibrosis possibly through suppression of TNF-alpha and PDGF as well as the inhibition on accumulation of inflammatory cells in the lung. Bleomycin 33-42 tumor necrosis factor Rattus norvegicus 102-111 9221384-11 1997 Tumor necrosis factor alpha (TNF-alpha) has been shown to be a key cytokine in bleomycin-induced fibrosing alveolitis as well as in IPF; it also exerts catabolizing effects. Bleomycin 79-88 tumor necrosis factor Rattus norvegicus 29-38 9596825-0 1996 [Consecutive study on alveolar macrophage release of tumor necrosis factor-alpha and platelet-derived growth factor in bleomycin-induced pulmonary fibrosis in rats]. Bleomycin 119-128 tumor necrosis factor Rattus norvegicus 53-80 9596825-1 1996 OBJECTIVE: Observe consecutively alveolar macrophage (AM) release of tumor necrosis factor-alpha (TNF-alpha) and platelet-derived growth factor (PDGF in bleomycin-induced pulmonary fibrosis in rats. Bleomycin 153-162 tumor necrosis factor Rattus norvegicus 69-96 9596825-1 1996 OBJECTIVE: Observe consecutively alveolar macrophage (AM) release of tumor necrosis factor-alpha (TNF-alpha) and platelet-derived growth factor (PDGF in bleomycin-induced pulmonary fibrosis in rats. Bleomycin 153-162 tumor necrosis factor Rattus norvegicus 98-107 1434213-5 1992 Using an experimental rat model of alveolitis induced by bleomycin, the expression of TNF-alpha mRNA in alveolar macrophages recovered by BAL was evaluated by Northern analysis. Bleomycin 57-66 tumor necrosis factor Rattus norvegicus 86-95 1434213-6 1992 Alveolar macrophages from bleomycin-treated rats expressed a significant level of TNF-alpha mRNA. Bleomycin 26-35 tumor necrosis factor Rattus norvegicus 82-91 34728227-9 2021 KEY FINDINGS: Carnosol treatment significantly reduced malondialdehyde, nitric oxide, protein carbonyl, tumor necrosis factor- alpha, interleukin-6 levels and myeloperoxidase activity in the lungs of rats exposed to bleomycin. Bleomycin 216-225 tumor necrosis factor Rattus norvegicus 104-132 1371205-0 1992 Changes in distribution, morphology, and tumor necrosis factor-alpha secretion of alveolar macrophage subpopulations during the development of bleomycin-induced pulmonary fibrosis. Bleomycin 143-152 tumor necrosis factor Rattus norvegicus 41-68 1371205-7 1992 Tumor necrosis factor-alpha secretion increased with time in 14- and 28-day samples of bleomycin-treated rats, particularly in subpopulations of densities 1.075 to 1.097 g/ml. Bleomycin 87-96 tumor necrosis factor Rattus norvegicus 0-27 1371205-9 1992 When coupled with previous studies suggesting that TNF-alpha plays a role in the fibrotic process in this disease model, these data indicate that AM of densities 1.075 to 1.097 g/ml are responsible for the production of TNF-alpha associated with bleomycin-induced pulmonary fibrosis. Bleomycin 246-255 tumor necrosis factor Rattus norvegicus 220-229 26629034-4 2015 Hodroxyproline content, myeloperoxidase (MPO) activity, tumor necrosis factor-alpha (TNF-alpha) and transforming growth factor-beta (TGF-beta) levels increased in the rat lung tissues after bleomycin administration, while superoxide dismutase (SOD) activity decreased in the rat lung tissues. Bleomycin 190-199 tumor necrosis factor Rattus norvegicus 56-83 26629034-7 2015 It partly reversed the bleomycin-induced increase of hydroxyproline content, MPO activity, TNF-alpha and TGF-beta levels in the lung tissues, significantly inhibited the bleomycin-induced decrease of SOD activity, Excessive collagen deposition was also inhibited by magnolol administration. Bleomycin 23-32 tumor necrosis factor Rattus norvegicus 91-100 31611754-9 2019 Hesperidin significantly inhibited BLM-induced down-regulated lung Nrf2 and HO-1 as well as up-regulated TNF-alpha, IL-1beta, IL-6, collagen-1, TGF-beta, and Smad-3 mRNA expressions. Bleomycin 35-38 tumor necrosis factor Rattus norvegicus 105-114 31611754-12 2019 Hesperidin alleviates BLM-induced IPF via inhibition of TGF-beta1/Smad3/AMPK and IkappaBalpha/NF-kappaB pathways which in turn ameliorate the modulation of oxido-inflammatory markers (Nrf2 and HO-1) and pro-inflammatory markers (TNF-alpha, IL-1beta, and IL-6) to reduce collagen deposition during pulmonary fibrosis. Bleomycin 22-25 tumor necrosis factor Rattus norvegicus 229-238 29793317-7 2018 RESULTS: Administration of bleomycin caused pulmonary fibrosis in rats as evidenced by characteristic structural changes in histopathology, increased inflammatory cells in bronchoalveolar lavage fluid, elevated lipid peroxidation marker, depleted endogenous antioxidants and increased inflammatory mediators (TNF-alpha, IL-6). Bleomycin 27-36 tumor necrosis factor Rattus norvegicus 309-318 29997685-0 2018 Combination of Salvia miltiorrhiza and ligustrazine attenuates bleomycin-induced pulmonary fibrosis in rats via modulating TNF-alpha and TGF-beta. Bleomycin 63-72 tumor necrosis factor Rattus norvegicus 123-132 26889245-9 2016 The treatment suppressed the increases in hydroxyproline content, MPO activity, TNF-alpha and TGF-beta levels and attenuated the reduction of SOD activity that were induced by bleomycin. Bleomycin 176-185 tumor necrosis factor Rattus norvegicus 80-89 26889245-6 2016 In addition, bleomycin administration increased the hydroxyproline content, myeloperoxidase (MPO) activity, tumor necrosis factor (TNF)-alpha and transforming growth factor (TGF)-beta levels and decreased the superoxide dismutase (SOD) activity in the rat lung tissues. Bleomycin 13-22 tumor necrosis factor Rattus norvegicus 108-141 26977316-8 2016 TNF-alpha, IL-1beta, and MDA levels and hydroxyproline content significantly increased (p < 0.01) and GPx and SOD activities significantly decreased in bleomycin group (p < 0.01). Bleomycin 155-164 tumor necrosis factor Rattus norvegicus 0-9 25672255-7 2015 In addition, BLM-induced increased expression of tumor necrosis factor-alpha, interleukin (IL)-1beta, IL-6, cyclooxygenase-2, prostaglandin E2, malondialdehyde, inducible nitric oxide synthase and nitric oxide in rats, which was also suppressed by Tan IIA injection. Bleomycin 13-16 tumor necrosis factor Rattus norvegicus 49-76 22582114-0 2012 Therapeutic hypercapnia prevents bleomycin-induced pulmonary hypertension in neonatal rats by limiting macrophage-derived tumor necrosis factor-alpha. Bleomycin 33-42 tumor necrosis factor Rattus norvegicus 122-149 22582114-7 2012 Inhibition of TNF-alpha signaling with the soluble TNF-2 receptor etanercept (0.4 mg/kg ip from days 1-14 on alternate days) prevented bleomycin-induced PHT without decreasing tissue macrophages and, similar to CO(2), had no effect on arrested alveolar development. Bleomycin 135-144 tumor necrosis factor Rattus norvegicus 14-23 22582114-8 2012 Our findings are consistent with a preventive effect of therapeutic hypercapnia with 7% CO(2) on bleomycin-induced PHT via attenuation of macrophage-derived TNF-alpha. Bleomycin 97-106 tumor necrosis factor Rattus norvegicus 157-166